Jenesis Innovative Research Awards™
The 2020/2021 Jenesis Innovative Research Awards program is accepting application submissions from October 1, 2020 – January 15, 2021. Please click here or visit www.utjenesisawards.com to submit your application.
STATEMENT OF PURPOSE
The Jenesis Innovative Research Awards™ provide support to US-based investigators who are engaged in innovative research that will advance scientific knowledge and enhance patient care in pulmonary hypertension (PH). Applicants must be part of an appropriate research group and under the supervision of a qualified mentor. Three awards will be issued annually.
The program provides financial support to 3 junior faculty for a 1-year period. Each award is funded up to $100,000. Recipients of these competitive awards will be selected by an independent Scientific Review Committee (SRC), comprised of leaders in the field of PH. The Committee will review complete applications and select research proposals based on their scientific merit, feasibility, and innovation. Announcement of award recipients will be made at an awards dinner hosted by the Committee and senior representatives from United Therapeutics. Please refer to the Applicant Eligibility section below to review the criteria applicants must meet to be considered for the award.
The program is designed to support basic, translational, clinical, and population research.
- Jenesis Outcomes Award™—exploring the science of clinical or patient-reported outcomes research
- Jenesis Clinical Award™—exploring populations with unmet treatment needs or novel treatment approaches
- Jenesis Pre-Clinical Award™—exploring the mechanisms behind PH disease processes and effects of therapies
The 2020-2021 award program will accept research proposals related to pulmonary hypertension. The program will support new original research. Proposals with significant budgetary or scientific overlap with funded research projects from a peer review agency or industry source will not be considered. If you plan to request treprostinil product for use in your Jenesis Award research proposal, you must clearly indicate the product and quantities requested in your proposal at the time of submission. Requests for product made after the initial proposal is submitted will not be considered.
ELIGIBLE SPONSORING INSTITUTION
These awards provide grants directly to the institutions of the selected researchers. The institutions are limited to US-based, nonprofit organizations, including medical and osteopathy schools, pharmacy schools, universities and colleges, and hospitals that demonstrate the ability to support the proposed research.
SCIENTIFIC REVIEW COMMITTEE (SRC)
Applicants will be assessed by an independent committee comprised of leaders in the field of PH. Scientific merit, originality, feasibility, and potential impact in the field of PH will be considered.
Ioana R. Preston, MD
Director, Pulmonary Hypertension Center
Tufts University School of Medicine
Stephen Chan, MD, PhD, FAHA
Director, Vascular Medicine Institute
Director, Center for Pulmonary Vascular Biology and Medicine
Professor of Medicine
Division of Cardiology, Department of Medicine
University of Pittsburgh School of Medicine and UPMC
Harrison W. Farber, MD
Professor of Medicine
Tufts University School of Medicine
Mardi Gomberg-Maitland, MD, MSc
Professor of Medicine
Director of the Pulmonary Hypertension Program
George Washington University
Anna Ryan Hemnes, MD
Division of Allergy, Pulmonary and Critical Care Medicine
Vanderbilt University School of Medicine
Steven M. Kawut, MD, MS
Professor of Medicine
Professor of Biostatistics and Epidemiology
Director, Pulmonary Hypertension/Pulmonary Vascular Disease Program
University of Pennsylvania
These awards are intended for junior faculty who are in the early stages of their career. An applicant may be a recipient of a career development (K) award or equivalent, but not an R category or other independent grants.
At the time of proposal submission, applicants must meet the following requirements:
- Hold a PhD degree or equivalent, or a doctoral-level clinical degree, such as MD, DO, or PharmD
- Be a US citizen, permanent resident, or hold a valid nonimmigrant visa. This visa must be valid for the one-year award period (July 1, 2021 – July 1, 2022)
- Be within five years from completion of final training in association with an academic research institution in the US at the time of the application
- Demonstrate a strong career interest in PH
- Have a research mentor with extensive experience in the field of PH
- Have at least 50% protected time to devote to research (instead of administrative or clinical duties that are not part of the research)
- Be able to complete the research within the 1-year award period
- Will have an academic appointment at the institution where the research will be conducted at the time of the award
Applications are evaluated based on the following criteria:
Criterion 1: Evaluation of the Applicant
- Mentor’s assessment of the applicant
- What is the applicant’s previous research experience and/or publications?
- Potential for a career in PH-related research
- Is the proposal well-structured and clearly written?
Criterion 2: Mentor/Training Plan and Environment
- The mentor should be an independent investigator in PH and have the experience to direct the proposed research training, as demonstrated by a track record of funding, productivity, and success with prior trainees
- Detailed description of the training plan should be provided by the mentor that demonstrates familiarity with the applicant’s career and developmental goals
- The mentor should ensure that the expertise, laboratory facilities, and protected time at the sponsoring institution will support the applicant’s progress toward his/her research goals
- Is the institution willing and able to commit the resources necessary for the applicant to complete the proposed research, including sufficient protected time?
Criterion 3: Evaluation of the Proposal
- Innovation and Significance: The proposal should be new, original, and address important concepts, methods, and/or technologies pertaining to PH
- Approach: The proposal should be appropriate for the applicant, given his or her education and experience. The conceptual framework, aims, preliminary data, design, methods, and analyses should be appropriate to the aims of the project. The proposal should acknowledge potential problems and address alternative approaches
- Feasibility: Substantial progress on the project should be feasible within a one-year time frame, with the proposed budget.
GUIDELINES FOR THE APPLICATION
Please have all application components completed and ready to submit. You will not be able to save and return to your application. Please be sure to complete all required fields or you will not be able to submit!
SUBMISSION DEADLINE: Friday, January 15, 2021, Midnight, Eastern Standard Time. No applications will be accepted after this date.
The applicant must take primary responsibility for the writing and preparation of the various proposal components, which are to be submitted electronically using the forms provided online. Other individuals (e.g., the mentor) will provide supporting documents that should be included with the application. The application components include:
– Applicant’s biographical sketch (NIH biosketch)
– Research Abstract
- The proposed research should be outlined in an abstract of no more than 500 words
The proposal should be a clear presentation of the project, single-spaced (using 11-point Arial font), and limited to 5 pages, not including the bibliography. Proposals of more than 5 pages will not be accepted. The proposal must include:
- Background and significance
- Preliminary results, if applicable
- Research design and methods, including any requests for treprostinil and quantities
- Anticipated results and potential pitfalls
- Figures and tables, if applicable, should be included in the body of the text
- Description of potential challenges and possible approaches to address them
- Bibliography (not included in the 5-page proposal count)
– Mentor’s biographical sketch (NIH biosketch)
– Letter of support from mentor which includes:
- Prior experience to direct the proposed research training, as evidenced by mentor’s track record regarding productivity, funding, and prior trainees
- Detailed description of the mentoring plan, including available resources allocated to the proposed research project, provision of protected time, and available laboratory facilities
- A plan for instruction and supervision in the responsible conduct of research
- A plan for the applicant’s career and developmental goals
– Letter of support from department head or division chief which includes confirmation of academic appointment and protected time for research
– Detailed Budget
- In order to maximize the benefits of the grant, indirect costs may not exceed 10% of the award and should be included in the budget
- There is no limitation on cost of supplies
- Travel costs are limited to $2,000 and may only be used to present data associated with this grant
- Salary and fringe benefits support may be allocated for the applicant or technician
- Salaries and fringe benefits support for mentors, post-doctoral fellows, or students may not be included
– Acknowledgement of Indirect Costs Limitation signed by an authorized institutional official. Please use the template provided on the program website.
– Applications for Funding. Please use the template provided on the program website.
– Certification of Faculty Appointment, signed by the applicant and department head. Please use the template provided on the program website.
If the research project includes investigations on human subjects, a copy of the submission to the institutional review board (IRB) must be submitted prior to award disbursement.
If the research project involves laboratory animals, researcher must certify that he/she will comply with all laws and regulations pertaining to the care and use of animals in research prior to award disbursement.
United Therapeutics will require IRB approval for clinical work and Institutional Animal Care Committee (IACUC) approval for nonclinical work prior to award disbursement.
The timeline, from application submission to award disbursement, is below:
Website Opens for Application: Thursday, October 1, 2020
Application Deadline: Friday, January 15, 2021, Midnight, EST
Applicant Notification: March 15, 2021
Award Disbursement: July 1, 2021, pending finalization of agreement between awardee’s institution and United Therapeutics
If you are selected as an award recipient, you and your institution must agree to the following items, including but not limited to:
– Exclusive Use of Funding
In order to maximize the benefits of the grant, indirect costs may not exceed 10% of the award and should be included in the budget.
The support of the Jenesis Innovative Research Awards Program™ must be acknowledged in any publication or abstracts resulting from research funded by this award. Draft publications must be submitted to United Therapeutics 30 days prior to submission to any scientific congress or journal.
– Intellectual Property
The host institution shall retain ownership of any inventions made by the institution and investigator during the conduct of the research.
– Change of Institution or Discontinuation
United Therapeutics must be notified immediately if the award recipient leaves the host institution or discontinues the research funded by the program. In the event the award recipient moves to another institution, the grant may be transferred at the sole discretion of the Scientific Review Committee. The new host institution must also agree to accept the terms and conditions of the existing award. In the event the host institution or award recipient is unable to continue or desires to discontinue the research before its completion, the institution will be required to return all unexpended funds.
Award recipients and their institutions will be required to enter into a written grant agreement with United Therapeutics prior to the receipt of funding.
For general inquiries, please call or email:
Attn: Jenesis Innovative Research Awards Coordinator
Kara Goss, MD
University of Wisconsin, Madison*
“Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study”
Yen-Chun (Charly) Lai, PhD
Indiana University School of Medicine, Indianapolis
“Mechanistic Role of Skeletal Muscle SIRT3 in Parenteral Treprostinil-Mediated Improvement of Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction”
Sara Vargas, PhD
The Warren Alpert Medical School of Brown University Brown University, Providence
“Health-Related Quality of Life: Patient-Focused Strategies for Measuring and Improving Sexual Health and Functioning Among Patients with Pulmonary Arterial Hypertension”
Benjamin Korman, MD
University of Rochester Medical Center, Rochester, NY
“Modulation of TNF-alpha as Cause and Treatment of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension”
Kurt Prins, MD, PhD
University of Minnesota, Minneapolis
“Protein O-GlcNACylation in RV Failure”
Samuel Rayner, MD
University of Washington, Seattle
“Establishing Patient-Specific Microvessel Models of Pulmonary Arterial Hypertension”
*At time of award
Martine and Bina Rothblatt founded United Therapeutics when their daughter Jenesis was diagnosed with PAH as a young girl. Faced with a stunning lack of information, support, and treatment options, they became committed to providing better therapies and eventually a cure for this disease. Jenesis and her story remain the inspiration behind United Therapeutics and the motivation for the Jenesis Innovative Research Awards, designed to award junior investigators dedicated to medical advancement for pulmonary hypertension through independent clinical, preclinical, and outcomes-based research.